within Pharmacolibrary.Drugs.ATC.C;

model C01BB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 3.3333333333333335,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Aprindine is a class Ib antiarrhythmic agent used for the treatment of cardiac arrhythmias such as ventricular and supraventricular arrhythmias. It acts primarily as a sodium channel blocker. Aprindine is not widely approved or used today, and in many regions its use has been discontinued or is not recommended due to safety concerns.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics parameters are estimated based on limited available literature and related antiarrhythmic drugs, as no comprehensive published pk model in humans could be identified. Estimates are for adult population with normal renal and hepatic function.</p><h4>References</h4><ol><li><p>Yokota, M, et al., &amp; Takahashi, A (1987). Non-linear pharmacokinetics of aprindine hydrochloride in oral administration. <i>Arzneimittel-Forschung</i> 37(2) 184–188. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2437934/&quot;>https://pubmed.ncbi.nlm.nih.gov/2437934</a></p></li><li><p>Kobari, T, et al., &amp; Hayakawa, H (1984). Dose-dependent pharmacokinetics of aprindine in healthy volunteers. <i>European journal of clinical pharmacology</i> 26(1) 129–131. DOI:<a href=&quot;https://doi.org/10.1007/BF00546721&quot;>10.1007/BF00546721</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6714286/&quot;>https://pubmed.ncbi.nlm.nih.gov/6714286</a></p></li><li><p>Taguchi, M, et al., &amp; Hashimoto, Y (2006). Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias. <i>Biological &amp; pharmaceutical bulletin</i> 29(3) 517–521. DOI:<a href=&quot;https://doi.org/10.1248/bpb.29.517&quot;>10.1248/bpb.29.517</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16508157/&quot;>https://pubmed.ncbi.nlm.nih.gov/16508157</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01BB04;
